EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, APRIL 6, 2017
Media Advisory: To contact corresponding study author Charles Blanke, M.D., email Wendy Lawton at firstname.lastname@example.org.
To place an electronic embedded link in your story: Links will be live at the embargo time: http://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2017.0243
Oregon’s Death with Dignity Act is the longest-running physician-aided dying program in the United States.
A new article published by JAMA Oncology from Charles Blanke, M.D., chairman of SWOG, a Portland-based worldwide network of researchers who design and conduct cancer trials, evaluates the usage and effectiveness of the law, which went into effect in 1997.
The article used data collected on the law to measure the number of deaths from self-administered lethal medication compared with the number of prescriptions written. The authors reviewed reports from 1998 to 2015 from the Oregon Health Authority, which collects compliance and prescribing information.
The authors report a total of 1,545 prescriptions were written and 991 patients (64 percent) died by using legally prescribed lethal medication.
The number of prescriptions that were written increased annually from 24 in 1998 to 218 in 2015. Most of the 991 patients who used lethal medication had cancer (77 percent). The most common reasons for physician-aided dying (PAD) were that activities of daily living were no longer enjoyable, as well as losses of autonomy and dignity, according to the article.
“We believe PAD is a promising area for formal, prospective research. Capturing more information on patients considering it (e.g. how many had an underlying diagnosis of depression, whether tumors were primary or recurrent, and time since diagnosis) would be of great interest in guiding cancer care delivery research,” the article concludes.
For more details and to read the full study, please visit the For The Media website.
(JAMA Oncol. Published online April 6, 2017. doi:10.1001/jamaoncol.2017.0243; available pre-embargo at the For The Media website.)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com